Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research & Development

Set Alert for Research & Development

Ocuphire Chalks Up Another Phase III Success For Nyxol

The company announced positive topline results for the drug in night vision disturbance and may conduct another pivotal trial as it focuses on myadriasis and presbyopia.

Business Strategies Ophthalmic

Agios CEO Fouse On Building A Sustainable Business Model

In the midst of another restructuring, the company is transitioning from a drug discovery company to a more externally focused R&D model; CEO Jackie Fouse talked to Scrip about the changes at Agios.

Business Strategies Companies

Enanta’s Path Forward Uncertain After RSV Failure

The US biotech’s RSV treatment candidate has failed a Phase II study in low-risk patients leaving some experts skeptical of its hopes for potential improved performance in a high-risk setting.

Clinical Trials Respiratory

Trial Hot Spot: Australia's Attractions To The Korean Industry

Ausbiotech's CEO and the Australian government’s Senior Trade and Investment Commissioner in South Korea talk to Scrip on the sidelines of the Bio Korea 2022 meeting about what makes Australia an attractive clinical trial destination for Korean and other foreign pharma firms, as well as about collaborations and other opportunities between the two countries.

Australia Clinical Trials

Moderna Spotlights Lung Delivery As One Of Its mRNA 'Dreams'

The company’s emphasis on artificial intelligence has played a leading role in development of lipid nanoparticles enabling delivery of mRNA to lung tissue under a partnership with Vertex.

Artificial Intelligence Business Strategies

Gene Therapy Biotechs Treating Sanfilippo Syndrome Hit Cash Crunch

Despite promising clinical data and solid regulatory plans, biotech firms hoping to address the unmet need in Sanfilippo Syndrome through gene therapy are facing financial struggles.

Companies Gene Therapy

Almirall Views Vitiligo As Next Dermatology Opportunity

As it prepares to file lebrikizumab for atopic dermatitis, the Spanish group is looking to expand into vitiligo through a collaboration with France’s Inserm Transfert to develop topical therapies for the condition where pale patches develop on the skin caused by the lack of melanin.

Dermatology Deals

Five Late-Breaking Studies To Look Out For At ASCO

Ahead of the American Society of Clinical Oncology meeting in early June, analysts at Biomedtracker have highlighted select high-impact late-breaking abstracts that are due to presented, including therapies from AbbVie, Gilead Sciences, Pfizer, Takeda, Amgen, AstraZeneca and Daiichi Sankyo.

Clinical Trials Companies

Gilead’s Lenacapavir On The Move Again As FDA Lifts Clinical Hold

The long-acting HIV drug’s greatest potential is for pre-exposure prophylaxis, where it would compete against ViiV’s long-acting injectable Apretude.

Infectious Diseases Clinical Trials

Valneva Hits New COVID-19 Jab Low With EC Contract Termination

Less than a year after signing a major advance purchase agreement to supply its inactivated COVID-19 jab to the EU, Valneva is faced with a termination that could hit its 2022 guidance.

Coronavirus COVID-19 Vaccines

Boryung’s Two-Track R&D Strategy: Innovative Drugs And Cash Cows

Boryung’s chief technology officer outlines R&D strategy to move forward as a Korea-based global pharma firm and how domestic pharmas are juggling new drug development and generating cash cows.

South Korea Business Strategies

Bristol’s Opdivo Stumbles On Its Way To First-Line Bladder Cancer Indication

The CheckMate-901 trial failed on one of its primary endpoints, but the company will continue the trial to explore additional primary endpoints.

Cancer ImmunoOncology
UsernamePublicRestriction

Register